WNT3A and breast cancer: This correlated expression was found in 26 out 32 breast cancers (75% + 6.25% = 81.25%) supporting the hypothesis of AurkA-miR-128-Wnt3a/β-catenin signaling also in clinical specimens (Fig. 6D).